The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional ... It also ranks No. 1 in New York according to Newsweek ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

Yo-Yo Dieting May Significantly Increase Kidney Disease Risk in People With Type 1 Diabetes Feb. 4, 2025 — Body-weight cycling (also known as yo-yo dieting) has been shown to significantly ...

Yo-Yo Dieting May Significantly Increase Kidney Disease Risk in People With Type 1 Diabetes Feb. 4, 2025 — Body-weight cycling (also known as yo-yo dieting) has been shown to significantly ...

Share on Pinterest GLP-1 ... 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people globally living with chronic obstructive pulmonary disease ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...

Over time, you might need to add other oral meds, insulin, or other injectable drugs, like a GLP-1 receptor ... t manage your diabetes properly. Vision problems, kidney disease, nerve damage ...